Shanzhi Gu

6.7k total citations
57 papers, 1.1k citations indexed

About

Shanzhi Gu is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shanzhi Gu has authored 57 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 18 papers in Hepatology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shanzhi Gu's work include Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Cancer Mechanisms and Therapy (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Shanzhi Gu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Cancer Mechanisms and Therapy (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Shanzhi Gu collaborates with scholars based in China, United States and Hong Kong. Shanzhi Gu's co-authors include Xinhan Zhao, Shangke Huang, Qing‐Rong Liu, Emmanuel S. Onaivi, Hiroki Ishiguro, Lin Zhao, Yujiao Zhang, Xin Jing, Xiaojin Zhang and Minna Luo and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Brain Research.

In The Last Decade

Shanzhi Gu

52 papers receiving 1.1k citations

Peers

Shanzhi Gu

ONCOL

HEPAT

IMMUN

Qinglong Li China

Bénédicte Foveau Canada

Yuyan Han United States

Takaaki Matsui Japan

Dagny Sandnes Norway

Rui Ni China

Weizhen Liu China

Yan Long China

Isao Kobayashi Japan

Qinglong Li China

Shanzhi Gu

189 ×0.4

ONCOL

425 ×1.2

149 ×0.7

HEPAT

195 ×1.1

79 ×0.4

IMMUN

Citations per year, relative to Shanzhi Gu Shanzhi Gu (= 1×) peers Qinglong Li

Countries citing papers authored by Shanzhi Gu

Since Specialization

Citations

This map shows the geographic impact of Shanzhi Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanzhi Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanzhi Gu more than expected).

Fields of papers citing papers by Shanzhi Gu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shanzhi Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanzhi Gu. The network helps show where Shanzhi Gu may publish in the future.

Co-authorship network of co-authors of Shanzhi Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Shanzhi Gu. A scholar is included among the top collaborators of Shanzhi Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shanzhi Gu. Shanzhi Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gu, Shanzhi, Yebin Guan, Kai Xie, et al.. (2025). Y-doped improved ZnIn2S4 promotes photocatalytic reduction of CO2 reaction. Materials Today Communications. 46. 112624–112624. 1 indexed citations

Dong, Jiahong, Satoshi Ogasawara, Ran Liu, et al.. (2025). LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 36. S62–S62. 1 indexed citations

Gao, Yuan, Shanzhi Gu, J.G. Li, et al.. (2025). Novel 2D/2D BiOIO3/Bi4O5Br2 heterojunction with oxygen vacancies and electron mediators as charge transfer channels for enhanced photocatalytic activity. Materials Today Communications. 45. 112373–112373. 1 indexed citations

Wang, Junmin, et al.. (2025). Saikosaponin D, a triterpene saponin from Bupleurum falcatum , restores circadian rhythm and attenuates hepatic fibrosis via Esr1-Per2 axis. Journal of Asian Natural Products Research. 28(1). 157–174.

Yuan, Jin, Yi Zheng, Lei Xu, et al.. (2024). 286P TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort. Annals of Oncology. 35. S120–S120. 1 indexed citations

Chan, Stephen L., Zhenggang Ren, Yuxian Bai, et al.. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.. Journal of Clinical Oncology. 42(16_suppl). 4110–4110. 16 indexed citations

Zhang, Jian, Yan Du, Ya Meng, et al.. (2023). 385MO A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors. Annals of Oncology. 34. S340–S340. 2 indexed citations

Shao, Guoliang, Hui Zeng, Bin Sun, et al.. (2023). 952P Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study. Annals of Oncology. 34. S597–S597. 1 indexed citations

Zhao, Haixia, Wenjun Wei, Xiaohui Yin, et al.. (2023). 1026MO A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors. Annals of Oncology. 34. S624–S624.

10.

Guo, Xin, et al.. (2022). Transcriptome-wide association study by different approaches reveals candidate causal genes for cannabis use disorder. Gene. 851. 147048–147048. 1 indexed citations

11.

Shao, Guoliang, Yuxian Bai, Xianglin Yuan, et al.. (2022). Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. EClinicalMedicine. 54. 101679–101679. 5 indexed citations

12.

Zeng, Li, et al.. (2022). A pan-cancer analysis of collagen VI family on prognosis, tumor microenvironment, and its potential therapeutic effect. BMC Bioinformatics. 23(1). 390–390. 16 indexed citations

13.

Qin, Shukui, Shanzhi Gu, Zhenggang Ren, et al.. (2021). Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer. 149(11). 1944–1954. 38 indexed citations

14.

Shi, Lin, Chenghui Zhou, Xiaoyan Long, et al.. (2021). 949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330). Annals of Oncology. 32. S826–S826. 5 indexed citations

15.

Zhang, Yujiao, Yizeng Fan, Xin Jing, et al.. (2021). OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression. Cancer Letters. 504. 104–115. 52 indexed citations

16.

Liu, Jun, et al.. (2021). Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features. Abdominal Radiology. 46(8). 3748–3757. 10 indexed citations

17.

Han, Rui, Shanzhi Gu, Yujiao Zhang, et al.. (2018). Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling. Scientific Reports. 8(1). 9575–9575. 80 indexed citations

18.

Ma, Jingyuan, et al.. (2017). Forensic Identification of Bipartite Patella Misdiagnosed as Patella Fracture. Journal of Forensic Sciences. 62(4). 1089–1091. 3 indexed citations

19.

Zhang, Zhe, Lei Hou, Feng Lu, et al.. (2015). An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13− tumor cells. Tumor Biology. 36(10). 8167–8175. 3 indexed citations

20.

Meng, Min, et al.. (2013). Region-specific expression of brain-derived neurotrophic factor splice variants in morphine conditioned place preference in mice. Brain Research. 1519. 53–62. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact